menu
    • menu
    [{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Lebrikizumab","moa":"IL-13","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":1.1000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":1.1000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly and Company","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly and Company"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"Tyrosine protein kinase receptor RET","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Lebrikizumab","moa":"IL-13","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":1.1000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":1.1000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly and Company","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly and Company"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Solanezumab","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"SARS-CoV-2 antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly ","highestDevelopmentStatusID":"1","companyTruncated":"Eli Lilly \/ Eli Lilly "},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Canada Pension Plan Investment Board ","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"SIG-001","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Sigilon Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Sigilon Therapeutics \/ Canada Pension Plan Investment Board ","highestDevelopmentStatusID":"5","companyTruncated":"Sigilon Therapeutics \/ Canada Pension Plan Investment Board "},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AC Immune","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"ACI3024","moa":"Tau aggregates","graph1":"Neurology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.11,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Solanezumab","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"JS016","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"Tyrosine protein kinase receptor RET","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ AbCellera","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ AbCellera"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"IL-17A","graph1":"Immunology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Evox Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"RNA interference","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Eli Lilly","amount2":1.23,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":1.23,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"JS016","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"IL-17A","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"IL-13","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Dermira","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Dermira"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"QurAlis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Zentalis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Abemaciclib","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Zentalis Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Zentalis Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Gantenerumab","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Hutchison China MediTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Fruquintinib","moa":"VEGFR","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Pieris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Paclitaxel","moa":"4-1BB receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"IL-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Sintilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":1.03,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Dulaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ National Institute of Health","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ National Institute of Health"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"LY-CoV-555","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Amgen","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Amgen"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Incyte"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Dulaglutide","moa":"GLP-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Sintilimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Incyte"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"IL-23p19 subunit","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Dexcom","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"Insulin Lispro","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Disarm Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"SARM1","graph1":"Neurology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":1.3600000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":1.3600000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Sermonix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lasofoxifene","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"FCN-338","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Eli Lilly","amount2":0.44,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.44,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"IL-17A","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Incyte"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Incyte"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"U.S. government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Bamlanivimab","moa":"Spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0.38,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.38,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ U.S. government","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ U.S. government"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Loxo-305","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Loxo Oncology Inc \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"NKTR-358","moa":"IL-2","graph1":"Immunology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ AbCellera","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ AbCellera"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"SIG-001","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sigilon Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Sigilon Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Sigilon Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Seed Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Eli Lilly","amount2":0.80000000000000004,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.80000000000000004,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Eli Lilly","amount2":0.56000000000000005,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.56000000000000005,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Bamlanivimab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Incyte"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Prevail Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Methylprednisolone","moa":"GBA1 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":1.04,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":1.04,"dosageForm":"Intracisternal Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"United Health Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Loxo Oncology Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Loxo-305","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ National Institute of Health","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ National Institute of Health"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"SIG-005","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Sigilon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Sigilon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sigilon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Evommune","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"IRAK4","graph1":"Dermatology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Evommune","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Evommune"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Blacksmith Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Metalloenzyme-targeted medicines","moa":"Metalloenzyme","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Eli Lilly","amount2":0.29999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"IL-17A","graph1":"Dermatology","graph2":"Preclinical","graph3":"DICE Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"DICE Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"DICE Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BRII-196","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ AbCellera","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ AbCellera"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Donanemab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Prevail Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"Methylprednisolone","moa":"GBA1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":1.04,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":1.04,"dosageForm":"Intracisternal Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"AK1780","moa":"P2X7 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.40999999999999998,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Seraxis","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"SR-01","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"Eli Lilly","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"R552","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0.95999999999999996,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.95999999999999996,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Merus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Bispecific antibody therapies","moa":"CD3","graph1":"Oncology","graph2":"Discovery","graph3":"Eli Lilly","amount2":1.6599999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.6599999999999999,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Biolojic Design","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Antibody-based therapy","moa":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Eli Lilly","amount2":0.12,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0.12,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Jubilant Cadista Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Incyte"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Donanemab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Glycopyrronium Tosylate","moa":"M3 receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Wipes","sponsorNew":"Eli Lilly \/ Journey Medical Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Journey Medical Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Jaguar Gene Therapy","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"JAG101","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0.14000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"IL-17A","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Incyte"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Incyte"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology","highestDevelopmentStatusID":"12","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"SciNeuro Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Antibody therapies","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ SciNeuro Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ SciNeuro Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Incyte"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"IL-17A","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"IL-17A","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Lupin","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Lupin"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Sun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Sun Pharma"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Mina Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"RNA-based Medicine","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Eli Lilly","amount2":1.25,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.25,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"LY3853113","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Eli lilly","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Eli lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"IL-23p19 subunit","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"ALX Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"ALX148","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ ALX Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ ALX Oncology"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Incyte"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"IBI362","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Donanemab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Protomer Technologies","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Acquisition","leadProduct":"Glucose Responsive Insulin","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":1,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":1,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Donanemab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Mina Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"RNA-based Medicines","moa":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Eli Lilly","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0.02,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Kumquat Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Eli Lilly","amount2":2.0699999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":2.0699999999999998,"dosageForm":"","sponsorNew":"Eli Lilly \/ Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Eli Lilly \/ Lilly"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"SIG-005","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Sigilon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Sigilon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sigilon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Incyte"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"IBI321","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Donanemab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"IL-13","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Dermira","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Dermira"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Quanterix","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Donanemab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Lycia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"LYTAC-based Therapeutics","moa":"Lysosomal targeting chimera","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Eli Lilly","amount2":1.6399999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":1.6399999999999999,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Series C Financing","leadProduct":"S011806","moa":"IL-17","graph1":"Dermatology","graph2":"IND Enabling","graph3":"DICE Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"DICE Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"DICE Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Almirall","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"IL-13","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"ProQR Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Editing Oligonucleotides","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Eli Lilly","amount2":1.3,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":1.3,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"GenEdit","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Series A Financing","leadProduct":"Genetic Medicine Encapsulated Polymeric Nanoparticles","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Care Access Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Abemaciclib","moa":"CDK","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Pfizer"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Incyte"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Hemogenyx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"CDX bi-specific Antibody","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Hemogenyx Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Hemogenyx Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2021","type":"Partnership","leadProduct":"Insulin Lispro","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Agilent Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Agilent","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Agilent"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly and Company","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly and Company"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"S011806","moa":"IL-17","graph1":"Dermatology","graph2":"Phase I","graph3":"DICE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"DICE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"DICE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"IBI319","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly and Company","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly and Company"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Incyte"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"CGRP","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Biohaven","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Biohaven"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Regor Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Eli Lilly","amount2":1.55,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1.55,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Foghorn Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Loxo Oncology Inc","amount2":0.38,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.38,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology","highestDevelopmentStatusID":"3","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"IL-23p19 subunit","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"IL-13","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Entos Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Nucleic acid-based Therapies","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0.45000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SIG-005","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Sigilon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Sigilon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sigilon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Veru","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Abemaciclib","moa":"CDK4","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"U.S. Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Bebtelovimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0.71999999999999997,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.71999999999999997,"dosageForm":"Intravenous","sponsorNew":"Eli Lilly \/ U.S. Government","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ U.S. Government"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Maruho Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Glycopyrronium Tosylate","moa":"M3 receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Wipes","sponsorNew":"Eli Lilly \/ Maruho Co","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Maruho Co"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bebtelovimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Eli Lilly \/ AbCellera Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ AbCellera Biologics"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bebtelovimab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"RosVivo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"RSVI-301","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Quanterix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Donanemab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pirtobrutinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Boehringer Ingelheim","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Ramucirumab","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Eli Lilly \/ Innovent Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Innovent Biologics"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Innovent Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Innovent Biologics"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Incyte"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"IL-13","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"IL-13","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Transcenta Holding","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Blosozumab","moa":"Sclerostin","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Artax Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"AX-158","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Inhalation","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"JAK","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"IL-23","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK4","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Veru","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK4","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"IL-13","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"D. E. Shaw Research","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"DES-7114","moa":"Kv1.3 channel","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0.54000000000000004,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.54000000000000004,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dulaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bimagrumab","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Aveo Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"HGF IgG1","graph1":"Oncology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ AVEO Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ AVEO Oncology"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bebtelovimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bimagrumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Not Applicable"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"DC-806","moa":"IL-17","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"DICE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Boehringer Ingelheim","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Lotus Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Eli Lilly","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Lotus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Lotus Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGF 1\/2\/3","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"Il-17 alpha","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Aclaris Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK4","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2","graph1":"Dermatology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Eli lilly","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Eli lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"VEGFR 1\/3","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ramucirumab","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Nimbus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"AMPK","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Eli Lilly","amount2":0.5,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.5,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"DC-806","moa":"IL-17","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"DICE Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"DC-806","moa":"IL-17","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"DICE Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Akouos","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"AK-OTOF","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Eli Lilly","amount2":0.48999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0.48999999999999999,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"5","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"DC-806","moa":"IL-17","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"DICE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bimagrumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pirtobrutinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imlunestrant","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Akouos","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"AK-OTOF","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Eli Lilly","amount2":1.1000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0.48999999999999999,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"5","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Donanemab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pirtobrutinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Sosei Heptares","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Eli Lilly","amount2":0.72999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0.72999999999999998,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"ProQR Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Large molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"RNA-based Therapy","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Eli Lilly","amount2":3.75,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","amount2New":3.75,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"TRexBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"TRB-051","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Eli Lilly","amount2":1.1599999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.1599999999999999,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Donanemab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pirtobrutinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Eli Lilly","amount2":1,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":1,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Immunogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Camptothecin-based Antibody Conjugate","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Discovery","graph3":"Eli Lilly","amount2":1.75,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.75,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Genesis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Eli Lilly","amount2":0.67000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.67000000000000004,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"PeptiDream","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Peptide-drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Eli Lilly","amount2":1.24,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.24,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Schrodinger","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Eli Lilly","amount2":0.42999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Kyttaro","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"LY3561774","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Kyttaro","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Kyttaro"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Abbisko Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Eli Lilly","amount2":0.26000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Doxorubicin","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Confo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CFTX-1554","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0.63,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.63,"dosageForm":"Liquid","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Bimagrumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AffaMed Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Galcanezumab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ AffaMed Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ AffaMed Therapeutics"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Solanezumab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Doxorubicin","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amphastar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Divestment","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":1.0800000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":1.0800000000000001,"dosageForm":"Powder","sponsorNew":"Eli Lilly \/ Amphastar Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Amphastar Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Zura Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Tibulizumab","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Zura Bio","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Zura Bio"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Rezpegaldesleukin","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Donanemab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"XtalPi","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Eli Lilly","amount2":0.25,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.25,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Verve Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Lipoprotein","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0.53000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.53000000000000003,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Galcanezumab-gnlm","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"DICE Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"DC-806","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Eli Lilly","amount2":2.3999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":2.3999999999999999,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Sigilon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Insulin Lispro","moa":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Eli Lilly","amount2":0.34000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amphastar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Divestment","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":1.0800000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":1.0800000000000001,"dosageForm":"Powder","sponsorNew":"Eli Lilly \/ Amphastar Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Amphastar Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"ALX Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Evorpacept","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"9","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Versanis Bio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Bimagrumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":1.9299999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1.9299999999999999,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"DICE Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"DC-806","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Eli Lilly","amount2":2.3999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":2.3999999999999999,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Versanis Bio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Bimagrumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":1.9299999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1.9299999999999999,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Sigilon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"SIG-002","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0.34000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Emergence Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Enfortumab Vedotin","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Veru","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boundless Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Abemaciclib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"177Lu-PNT2002","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":1.3999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.3999999999999999,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Mablink Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Elektrofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"Eli Lilly","amount2":0.46999999999999997,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.46999999999999997,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"BioAge Labs","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Azelaprag","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Beam Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"VERVE-101","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Eli Lilly","amount2":0.59999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.59999999999999998,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Mirikizumab-mrkz","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Prism Biolab","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Eli Lilly","amount2":0.66000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.66000000000000003,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Galcanezumab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"177Lu-PNT2002","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":1.3999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.3999999999999999,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pirtobrutinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Zuellig Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Zuellig Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Zuellig Pharma"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Foghorn Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"FHD-909","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Lasmiditan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Ildong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pirtobrutinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Donanemab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Donanemab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Sleep","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Donanemab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"5 Prime Sciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Aktis Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Radiopharmaceutical-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Eli Lilly","amount2":1.1599999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.1599999999999999,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"TRexBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"TRB-051","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Eli Lilly","amount2":1.1599999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.1599999999999999,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"QurAlis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"QRL-204","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0.62,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.62,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Insulin Efsitora Alfa","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Augustine Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Small molecule","year":"2024","type":"Series A Financing","leadProduct":"AGT100216","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Alloy Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Isomorphic Labs","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Eli Lilly","amount2":1.75,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.75,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Totus Medicines","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Radionetics Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":1,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Aclaris Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Large molecule","year":"2024","type":"Expanded Collaboration","leadProduct":"ADC-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Artax Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"AX-158","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Morphic Therapeutic","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"MORF-057","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":3.2000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tradipitant","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Donanemab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Insulin Efsitora Alfa","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"HAYA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":1,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Genetic Leap","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Oblique Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Galcanezumab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Organon"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eva Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"EGYPT","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Baricitinib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Axcelead","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Donanemab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Foghorn Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"FHD-909","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Insitro","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Insitro","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"siRNA-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Insitro","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Insitro"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"KeyBioscience","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Expanded Collaboration","leadProduct":"LY3541105","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":1.3999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Donanemab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Donanemab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyclix Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"INX-315","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Verge Genomics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0.71999999999999997,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Muvalaplin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Eli Lilly

    Menu

    Eli Lilly

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Muvalaplin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lilly Pill Cuts Genetic Form of Cholesterol Nearly 86% in Study

                            Details : LY3473329 (muvalaplin) is a potent, multivalent, small molecule that inhibits the formation of Lp(a) by blocking interaction between apoA and apoB in patients with high risk of cardiovascular disease.

                            Brand Name : LY3473329

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 18, 2024

                            Lead Product(s) : Muvalaplin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirzepatide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lilly’s Tirzepatide Cuts Heart Failure Risks by 38% in HFpEF Patients with Obesity

                            Details : Zepbound (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently being studied for adults with heart failure with preserved ejection fraction and obesity.

                            Brand Name : Zepbound

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            November 16, 2024

                            Lead Product(s) : Tirzepatide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Donanemab

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lilly's Adjusted Kisunla Regimen Reduces Brain Swelling in Trial

                            Details : Kisunla (donanemab) is an amyloid beta plaque inhibitor, a humanized IgG1 MAb, approved in adults with mild cognitive impairment and mild dementia stage of early symptomatic Alzheimer's disease.

                            Brand Name : Kisunla

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 29, 2024

                            Lead Product(s) : Donanemab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirikizumab

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lilly's Mirikizumab Shows Long-Term Efficacy for UC And Crohn's Disease

                            Details : Omvoh (mirikizumab) is the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis & crohn's disease in adults.

                            Brand Name : Omvoh

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 28, 2024

                            Lead Product(s) : Mirikizumab

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirzepatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eli Lilly Gets Nod to Launch Weight-Loss Drug in Hong Kong

                            Details : Mounjaro (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently it is indicated for the treatment of type 2 diabetes mellitus and obesity.

                            Brand Name : Mounjaro

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            October 28, 2024

                            Lead Product(s) : Tirzepatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Donanemab

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lilly’s Donanemab Offers Hope for Alzheimer’s After Lecanemab Rejection

                            Details : Kisunla (donanemab) is an amyloid beta plaque inhibitor, a humanized IgG1 MAb, approved in adults with mild cognitive impairment and mild dementia stage of early symptomatic Alzheimer's disease.

                            Brand Name : Kisunla

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 25, 2024

                            Lead Product(s) : Donanemab

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirikizumab

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lilly Phase 3 Study Shows Mirikizumab Efficacy in Crohn’s Disease Over Ustekinumab

                            Details : Omvoh (mirikizumab) is the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis (UC) in adults.

                            Brand Name : Omvoh

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 14, 2024

                            Lead Product(s) : Mirikizumab

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FHD-909

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Foghorn Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Foghorn Doses First Patient with SMARCA2 Inhibitor For Solid Tumors

                            Details : FHD-909 is a first-in-class oral BRM selective inhibitor. It is being evaluated in preclinical studies for the treatment of BRG1 mutated non-small cell lung cancer.

                            Brand Name : FHD-909

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 10, 2024

                            Lead Product(s) : FHD-909

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Foghorn Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : siRNA-based Therapy

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Preclinical

                            Sponsor : Insitro

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Lilly, insitro Enter Strategic Agreements for Metabolic Diseases

                            Details : insitro has an option to in-license GalNAc delivery technology from Lilly that it will combine with two different siRNA, each specifically directed toward a different target in the liver.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 10, 2024

                            Lead Product(s) : siRNA-based Therapy

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Preclinical

                            Sponsor : Insitro

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LY3541105

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Recipient : KeyBioscience

                            Deal Size : $1,400.0 million

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            KeyBioscience Announces Extension of Strategic Collaboration with Lilly

                            Details : Lilly will receive worldwide rights to develop and commercialize Dual Amylin Calcitonin Receptor Agonists (DACRA), a new class of potential treatments for obesity and related disorders.

                            Brand Name : LY3541105

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 10, 2024

                            Lead Product(s) : LY3541105

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Recipient : KeyBioscience

                            Deal Size : $1,400.0 million

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth